MTOR and Buschke-Ollendorff syndrome: Due to the fact, that all lung transplant recipients were treated with either cyclosporine A or tacrolimus and that only 3 of the patients in the study had an immunosuppressive regime including a mTOR inhibitor (Sirolimus or Everolimus; 2 patients with BOS, 1 patient without BOS) we do not expect any influence on cardiac mass due to the immunosuppression regime in the presented study.